← All trials
NCT01643967
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2012
- Primary completion
- Dec 31, 2012
- Completion date
- Jan 31, 2013
- First posted
- Jul 18, 2012
- Last posted
- Jul 18, 2012
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Philozon Geradores de Ozonio LTDALead sponsor
- Hospital Santa Marcelina, Sao Paulo, BrasilOverall official - principal investigator
- Hospital Santa Marcelina, Sao Paulo, BrasilOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.